A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

COVID-19 treatment called into question after major study In a nutshell A major study of 1.6 million seniors found that ...

As COVID-19 surged across the US starting in 2020, so too did the use of repurposed medications such as hydroxychloroquine and ivermectin to treat COVID-19 infections. Use of these medications ...

Researchers at the Wuhan Institute of Virology have detected a new coronavirus in bats that is capable of entering human ...

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as ...

With the acute phase of the Covid-19 pandemic fading even as the coronavirus persists and evolves, a new normal is taking shape around the world. In a small study, patients with the syndrome were ...

Paxlovid may offer marginal benefits for low-risk children with COVID-19; however, among high-risk children with COVID-19, Paxlovid is a safe oral option.

Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

Here, the authors use full-length Mpro protein as substrate and demonstrate that L50F can promote the formation of enzyme-substrate complex and thus contribute to nirmatrelvir resistance.